Rare diseases
Investigational molecules
Locations
Recruiting trials first
22 clinical trials in this condition
AustriaAustria
ItalyAustriaIn short
Hereditary angioedema is a rare genetic condition that causes sudden, unpredictable episodes of severe swelling in different parts of the body. Because HAE symptoms can look similar to more common conditions, getting an accurate diagnosis often takes time—sometimes years. Understanding when to seek testing and what diagnostic methods are available is essential for anyone experiencing unexplained swelling episodes.
If you experience recurring episodes of swelling that come and go without an obvious cause, you should consider talking to your doctor about testing for hereditary angioedema. This is especially important if the swelling affects your hands, feet, face, lips, or genitals, or if you have severe abdominal pain that comes in attacks along with nausea, vomiting, or diarrhea.
Family history plays a crucial role in deciding who should be tested. If you have a parent with HAE, you have a 50 percent chance of inheriting the condition yourself. However, the absence of family history doesn't rule out HAE. Research indicates that as many as 25 percent of HAE cases result from a spontaneous genetic mutation that occurs at conception, meaning the condition appears for the first time in a family without any previous known cases.
Symptoms of HAE usually appear early in life, most often by age 13. About half of all children with the most common types of HAE show symptoms by age 10, though symptoms can appear as early as age 2. The severity and frequency of attacks often increase during puberty due to hormonal changes.
Because HAE is so rare, affecting only about 1 in 50,000 people, many doctors have never encountered it. This unfamiliarity often leads to misdiagnosis, and it can take as long as a decade to obtain an accurate diagnosis after symptoms first appear. Doctors may initially rule out more common conditions with similar symptoms, such as contact dermatitis, appendicitis, or irritable bowel syndrome.
You should also seek testing if you notice certain warning signs before swelling episodes begin. These early signals can include extreme fatigue, muscle aches, tingling sensations, headache, hoarseness, mood changes, or a flat, non-itchy rash. About 25 percent of people with HAE develop this distinctive rash, called erythema marginatum, which often appears before or during an attack.
Diagnosing hereditary angioedema requires more than just observing symptoms. Because HAE can mimic other conditions, doctors use specific blood tests to confirm the diagnosis and distinguish it from other forms of angioedema. The diagnostic process typically begins with a physical examination and a detailed medical history, followed by specialized laboratory testing.
The main diagnostic approach for HAE involves measuring the level and function of a blood protein called C1-inhibitor (C1-INH). This protein normally acts like a brake in your body's inflammatory system, controlling the production of another substance called bradykinin. When C1-inhibitor is deficient or doesn't work properly, bradykinin levels rise, causing fluid to leak from blood vessels into surrounding tissues, which leads to swelling.
Doctors typically order three specific blood tests to diagnose HAE. The first test measures the amount of C1-inhibitor protein in your blood, checking whether you have enough of this protein. The second test evaluates how well your C1-inhibitor protein actually functions, even if the amount seems normal. The third test measures complement component 4 (C4), another protein that is often abnormally low during HAE episodes.
Based on these test results, doctors can identify which type of HAE you have. Type I HAE, which accounts for about 85 percent of all cases, occurs when your body doesn't make enough C1-inhibitor protein. In Type II HAE, your body produces normal or even elevated amounts of C1-inhibitor, but the protein doesn't function correctly. Together, these two types affect approximately 1 in 50,000 people worldwide.
In addition to measuring protein levels, doctors may recommend genetic testing to identify the specific mutation causing HAE. The vast majority of HAE cases result from variants in the SERPING1 gene, which provides instructions for making the C1-inhibitor protein. More than 150 different mutations in this gene have been identified in patients with HAE.
Genetic testing becomes particularly important when diagnosing HAE with normal C1-inhibitor levels, a rare form where blood tests show normal amounts of functioning C1-inhibitor protein. In these cases, doctors look for variants in other genes, such as the F12 gene, which provides instructions for making coagulation factor XII. Mutations in this gene cause cells to produce an overactive version of factor XII, leading to excessive bradykinin production and swelling episodes.
One critical aspect of diagnosing HAE is distinguishing it from allergic angioedema, which is much more common. Unlike allergic reactions, HAE doesn't cause hives or itching. The swelling in HAE also doesn't respond to the medications typically used for allergies, such as antihistamines, corticosteroids, or epinephrine. This lack of response to standard allergy treatments often provides an important clue that leads doctors to test for HAE.
Doctors also need to distinguish hereditary angioedema from acquired angioedema with C1-inhibitor deficiency. While both conditions involve C1-inhibitor problems, acquired angioedema usually appears later in life, often after the fourth decade, whereas HAE typically presents during the first two decades. The age of onset, along with family history and specific blood test patterns, helps doctors make this distinction.
Beyond blood tests, your doctor will ask detailed questions about your symptoms and their patterns. They'll want to know where swelling has occurred, how often episodes happen, how long they last, and whether you've noticed any triggers or warning signs. Questions about family members who may have experienced similar symptoms or unexplained deaths are also important, as previous cases in the family might have been undiagnosed.
Your doctor may ask about specific situations that preceded swelling episodes, such as physical activities like typing or pushing a lawn mower, dental procedures, surgeries, illnesses like colds or flu, emotional stress, or the use of certain medications. Women may be asked about connections between their menstrual cycle, pregnancy, or hormone-based medications and the frequency or severity of attacks.
When patients with HAE consider participating in clinical trials to test new treatments, they typically need to undergo additional diagnostic evaluations beyond standard clinical testing. These requirements ensure that study participants meet specific criteria and that researchers can accurately measure how well experimental treatments work.
Clinical trials usually require confirmed documentation of HAE diagnosis through laboratory results showing either low C1-inhibitor levels (Type I HAE) or dysfunctional C1-inhibitor (Type II HAE). Researchers need these baseline measurements before starting any experimental treatment to establish a clear starting point for comparison.
Many clinical trials also require patients to document the frequency and severity of their HAE attacks over a specific period before enrollment. This documentation might include keeping a detailed diary of attack locations, duration, symptoms, treatments used, and how the attacks affected daily activities. Some trials provide specific tools or apps for tracking this information consistently.
Age requirements vary by clinical trial. Some studies focus specifically on adult patients aged 18 and older, while others include adolescents aged 12 and above, and some may enroll children as young as 2 years old. The eligibility criteria depend on what age groups the experimental treatment is being studied for and what safety data already exists.
Clinical trial screening may involve additional blood tests beyond standard HAE diagnostics to check overall health status, kidney function, liver function, and to ensure the patient doesn't have other medical conditions that might interfere with the study. Patients may also need to undergo physical examinations and provide complete medical histories to research teams.
Genetic testing may be required for some clinical trials, particularly those studying HAE with normal C1-inhibitor levels or those investigating how specific genetic mutations respond to new treatments. Understanding which genetic variant causes your HAE can help researchers develop more targeted therapies in the future.
For clinical trials testing preventive medications, researchers may require evidence of a minimum number of HAE attacks per month over a specified observation period. This ensures the study includes patients who experience frequent enough attacks to measure whether the experimental treatment reduces attack frequency. Conversely, trials testing treatments for acute attacks may have different requirements about attack frequency and severity.
The outlook for people with hereditary angioedema has improved dramatically in recent years due to advances in understanding the condition and the development of new treatments. The prognosis depends largely on whether the condition is properly diagnosed and managed. When untreated, HAE attacks typically last between 24 and 72 hours, though some episodes can persist for more than a week. On average, untreated individuals experience swelling episodes every 1 to 2 weeks, though the frequency varies greatly even among members of the same family.
With proper management, including preventive medications and treatments for acute attacks, most people with HAE can lead normal, productive lives. The availability of multiple FDA-approved therapies means that doctors and patients now have options to develop personalized treatment plans. However, the unpredictable nature of HAE attacks can still affect quality of life, work productivity, and daily activities. Studies show that 34 percent of patients report their physical health or emotional problems interfere with social activities at least some of the time, and patients report HAE symptoms affecting their work for an average of 2.3 hours over a seven-day period.
Hereditary angioedema can be life-threatening, particularly when swelling affects the airways. Historically, before modern treatments became available, airway swelling could lead to asphyxiation and death. Despite new treatments, airway swelling remains the most feared complication and can still be fatal without immediate medical intervention. Fortunately, upper airway involvement is rare compared to swelling in other body parts.
With current diagnostic capabilities and treatment options, the long-term survival rate for people with properly managed HAE is generally favorable. Early diagnosis, access to appropriate medications, patient education about recognizing early warning signs, and having emergency treatment plans in place all contribute to better outcomes. Family members should be aware of the hereditary nature of the condition, as each child of a person with HAE has a 50 percent chance of inheriting it, and early diagnosis in children can help prevent life-threatening complications.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
